首页> 外文OA文献 >Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform

【2h】

Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform

机译：PARP抑制剂在BRCA相关HER2阴性转移性乳腺癌现代治疗算法中的作用和位置。基于“onCoforum”平台的教育和讨论事件的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study [J] . Vuylsteke P., Huizing M., Petrakova K., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第11期

机译：Pictilisib PI3Kinase抑制剂（一种磷脂酰肌醇3激酶[PI3K]抑制剂）+紫杉醇，用于治疗激素受体阳性，HER2阴性，局部复发或转移性乳腺癌：多中心，安慰剂对照，II期随机化的中期分析佩吉研究
2. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial [J] . Nanni O., Amadori D., De Censi A., Breast cancer research and treatment. . 2019,第2期

机译：二甲双胍加上化疗与化疗单独在英雄2阴性转移性乳腺癌的一线治疗中。 Myme随机化，第2期临床试验
3. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. [J] . Finn RS, Press MF, Dering J Journal of Clinical Oncology . 2009,第24期

机译：在紫杉醇联合拉帕替尼或安慰剂作为HER2阴性或未知转移性乳腺癌的一线治疗的随机试验中，雌激素受体，孕激素受体，人表皮生长因子受体2（HER2）和表皮生长因子受体的表达和拉帕替尼的获益。
4. Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis [O] . Francesca Poggio, Marco Bruzzone, Marcello Ceppi, 2018

机译：单药PARP抑制剂治疗BRCA突变的HER2阴性转移性乳腺癌的患者：系统评价和荟萃分析
5. Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice [O] . L. G. Zhukova, E. I. Khatkova, P. S. Feoklistova, 2019

机译：Palbociclib在激素受体阳性Her2阴性转移性乳腺癌治疗中的作用。随机试验的概括结果和真正的临床实践

Role and place of PARP inhibitors in the modern treatment algorithm of BRCA-associated HER2-negative metastatic breast cancer. Results of the educational and discussion events based on the “OncoForum” platform

著录项

引文网络

相似文献

相关主题

期刊订阅